President Biden Signs Medical Marijuana Research Bill

-Bloomberg

-Bloomberg

Total
0
Shares
Related Posts
Read More

Crocs Lowers Its FY23 Outlook: Now Sees Revenue Of $3.905B-$3.94B (Prior $4.00B-$4.06B) Vs. Consensus Of $4.01B; Adjusted EPS Of $11.55-$11.85 (Prior $11.83-$12.22) Vs. Consensus Of $12.09, And Adjusted Operating Margin Of ~27%

Full Year 2023 With respect to 2023, we expect: Consolidated revenue growth to now be approximately 10% to 11% compared to 2022, resulting in revenues of approximately $3,905 to $3,940 million at currency rates as of

CROX